Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints
NCT ID: NCT05846451
Last Updated: 2024-12-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
EARLY_PHASE1
16 participants
INTERVENTIONAL
2023-06-01
2025-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. How does kratom affect the manner in which oxycodone is metabolized (broken down and removed) by the body?
2. Does kratom change the effects oxycodone exerts on the body?
Healthy adult participants will complete four study arms, during which they will be given the following:
* Kratom (as a tea)
* A single dose of oxycodone (as a tablet)
* Kratom tea and a single dose of oxycodone
* Kratom tea for four days, then kratom tea and a single dose of oxycodone
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Arm 1: a single low dose of kratom (by mouth, as a tea)
* Arm 2: a single low dose of immediate-release oxycodone (by mouth, as a tablet)
* Arm 3: a single low dose of kratom tea and a single low dose of oxycodone
* Arm 4: daily at-home self-administration of kratom tea for four days, followed immediately by a single low dose of kratom tea and a single low dose of oxycodone in the research setting
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Sixteen non-naive\* participants (8 males, 8 females) will be administered a single low dose (2 g) of a well-characterized kratom product by mouth as a tea. Pupil diameter will be measured from 0-12 hours. A washout of at least 10 days will separate Arms 1 and 2.
\*Non-naive subjects are defined as intermittent users who consume 2-8 g kratom at least once per month but no more than three times daily within the last six months prior to screening and are willing to abstain for several weeks
Kratom
Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two grams of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Participants will drink the tea within 15 minutes.
Arm 2
The same 16 participants will be administered a single low dose (10 mg) of immediate-release oxycodone by mouth as a tablet. Plasma, pupil diameter measurements, and urine will be collected from 0-24 hours. A washout of at least 2 days will separate Arms 2 and 3.
Oxycodone
Immediate-release oral tablet, 10 mg
Arm 3
The same 16 participants will be administered a single low dose (2 g) of kratom as a tea. After 15 minutes, the subjects will be administered a single low dose (10 mg) of oxycodone as a tablet by mouth. Plasma, pupil diameter measurements, and urine will be collected from 0-24 hours. A washout of at least 10 days will separate Arms 3 and 4.
Kratom
Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two grams of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Participants will drink the tea within 15 minutes.
Oxycodone
Immediate-release oral tablet, 10 mg
Arm 4
The same 16 participants will self-administer a single low dose (2 g) of kratom as a tea once daily at home. On the fifth day, subjects will return to the research setting, where they will be administered a single low dose (2 g) of kratom, followed 15 minutes later by a single low dose (10 mg) of oxycodone by mouth. Plasma, pupil diameter measurements, and urine will be collected from 0-24 hours.
Kratom
Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two grams of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Participants will drink the tea within 15 minutes.
Oxycodone
Immediate-release oral tablet, 10 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Kratom
Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two grams of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Participants will drink the tea within 15 minutes.
Oxycodone
Immediate-release oral tablet, 10 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body weight between 130 and 250 pounds (60-115 kg) and body mass index between 19 and 30
* Not taking any medications (prescription and non-prescription) or dietary supplements/botanical products known to alter the pharmacokinetics of either oxycodone or kratom
* Willing to abstain from consuming dietary supplements/botanical products and fruit juices for several weeks
* Willing to abstain from cannabis/marijuana, hemp, and THC- and/or CBD-containing products for several weeks
* Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and morning of any inpatient visit
* Willing to abstain from consuming alcoholic beverages for one day prior to any inpatient visit
* Willing to use an additional method of contraception that does not include oral contraceptive pills, patches, or other hormonal methods (such as abstinence, copper IUD, or condoms)
* Have consumed kratom previously and tolerated it well without any unpleasant effects
* Willing to abstain from kratom for several weeks
* Have consumed any opioid previously and tolerated it well without any unpleasant effects or addiction
* Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for the subject to comply with the requirements of the study
* Geographically located within a 40-mile radius of Spokane and have the time to participate
Exclusion Criteria
* People who weigh less than 130 pounds or more than 250 pounds
* People with a body mass index less than 19 or greater than 30
* Any current major illness or chronic illness including but not limited to kidney disease, hepatic disease, diabetes mellitus, hypertension, coronary artery disease, chronic obstructive pulmonary disease, cancer, or HIV/AIDS
* No previous exposure to kratom
* No previous exposure to an opioid
* History of anemia or any other significant hematologic disorder
* History of substance abuse, dependence, or addiction or major psychiatric illness
* A need for chronic opioid analgesics
* Use of opioid analgesics 3 weeks prior to initiation of the study
* An imminent likely need for opioid analgesics (e.g., planned dental or surgical procedure)
* Pregnant or nursing
* History of allergy or intolerance to kratom, other opioids, or oxycodone
* Taking concomitant medications, both prescription and non-prescription (including dietary supplements/botanical products), known to alter the pharmacokinetics of kratom or oxycodone
* Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data
* History of sleep apnea
* Any prior use of amphetamines, benzodiazepines, cocaine, MDMA, opioids, PCP, or other drugs for recreational purposes
* Use of cannabis/marijuana, hemp, THC-containing products, CBD-containing products, or CBD within the last month
* Out-of-range clinical laboratory value that the study physician considers participation in the study a health risk
* Inability to speak, read, and understand English
21 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Washington State University
OTHER
National Center for Complementary and Integrative Health (NCCIH)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mary Paine
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Washington State University College of Pharmacy and Pharmaceutical Sciences
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mary Paine, PhD, RPh
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19633
Identifier Type: -
Identifier Source: org_study_id